[1]
|
National Cancer Center, “Cancer Statistics in Japan,” 2005.
http://www.ncc.go.jp/en/statistics/index.html
|
[2]
|
C. M. Haskelled, “Cancer Treatment,” 5th Edition, WBS-aunders Co., Philadelphia, 2001.
|
[3]
|
B. Levin, “Gallbladder Carcinoma,” Annals of Oncology, Vol. 10, No. 3, 1999, pp. 129-130.
doi:10.1023/A:1008325911628
|
[4]
|
S. Kobayashi, H. Nagano, S. Marubashi, Y. Takeda, M. Tanemura, K. Konishi, Y. Yoshioka, T. Inoue, Y. Doki and M. Mori, “Impact of Postoperative Irradiation after Non-Curative Resection of Hilar Biliary Cancer,” Journal of Surgical Oncology, Vol. 100, No. 8, 2009, pp. 657-662. doi:10.1002/jso.21409
|
[5]
|
S. Kobayashi, H. Nagano, S. Marubashi, H. Wada, H. Eguchi, Y. Takeda, M. Tanemura, Y. Doki and M. Mori, “Multi-Detector Computed Tomography for Preoperative Prediction of Postsurgical Prognosis of Patients with Extrahepatic Biliary Cancer,” Journal of Surgical Oncology, Vol. 101, No. 5, 2010, pp. 376-383.
|
[6]
|
S. Kobayashi, H. Nagano, S. Marubashi, H. Wada, H. Eguchi, Y. Takeda, M. Tanemura, K. Umeshita, Y. Doki and M. Mori, “Treatment of Borderline Cases for Curative Resection of Biliary Tract Cancer,” Journal of Surgical Oncology, In Press.
|
[7]
|
S. Miyakawa, S. Ishihara, A. Horiguchi, T. Takada, M. Miyazaki and T. Nagakawa, “Biliary Tract Cancer Treatment: 5584 Results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan,” Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 16, No. 1, 2009, pp. 1-7.
doi:10.1007/s00534-008-0015-0
|
[8]
|
J. Furuse, T. Takada, M. Miyazaki, S. Miyakawa, K. Tsukada, M. Nagino, S. Kondo, H. Saito, T. Tsuyuguchi, K. Hirata, F. Kimura, H. Yoshitomi, S. Nozawa, M. Yoshida, K. Wada, H. Amano and F. Miura, “Japanese Association of Biliary Surgery; Japanese Society of Hepato-Biliary-Pancreatic Surgery; Japan Society of Clinical Oncology. Guidelines for chemotherapy of biliary tract and ampullary carcinomas,” Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 15, No. 1, 2008, pp. 55-62.
doi:10.1007/s00534-007-1280-z
|
[9]
|
F. Eckel and R. M. Schmid, “Chemotherapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials,” British Journal of Cancer, Vol. 96, No. 6, 2007, pp. 896-902. doi:10.1038/sj.bjc.6603648
|
[10]
|
N. Yonemoto, J. Furuse, T. Okusaka, K. Yamao, A. Funakoshi, S. Ohkawa, N. Boku, K. Tanaka, M. Nagase, H. Saisho and T Sato, “A Multi-Center Retrospective Analysis of Survival Benefits of Chemotherapy for Unresectable Biliary Tract Cancer,” Japanese Journal of Clinical Oncology, Vol. 37, No. 11, 2007, pp. 843-851.
doi:10.1093/jjco/hym116
|
[11]
|
J. W. Valle, H. Wasan, P. Johnson, E. Jones, L. Dixon, R. Swindell, S. Baka, A. Maraveyas, P. Corrie, S. Falk, S. Gollins, F. Lofts, L. Evans, T. Meyer, A. Anthoney, T. Iveson, M. Highley, R. Osborne and J. Bridgewater, “Gemcitabine Alone or in Combination with Cisplatin in Patients with Advanced or Metastatic Cholangiocarcinomas or Other Biliary Tract Tumours: A Multicentre Randomised Phase II Study—The UK ABC-01 Study,” British Journal of Cancer, Vol. 101, No. 4, 2009, pp. 621-527.
doi:10.1038/sj.bjc.660
|
[12]
|
J. Valle, H. Wasan, D. H. Palmer, D. Cunningham, A. Anthoney, A. Maraveyas, S. Madhusudan, T. Iveson, S. Hughes, S. P. Pereira, M. Roughton and J. Bridgewater, “ABC-02 Trial Investigators. Cisplatin Plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer,” New England Journal of Medicine, Vol. 362, No. 14, 2010, pp. 1273-1281. doi:10.1056/NEJMoa0908721
|
[13]
|
M. S. Aapro, C. Martin and S. Hatty, “Gemcitabine—a Safety Review,” Anticancer Drugs, Vol. 9, No. 3, 1998, pp. 191-201. doi:10.1097/00001813-199803000-00001
|
[14]
|
Y. Murakami, K. Uemura, T. Sudo, Y. Hayashidani, Y. Hashimoto, H. Nakamura, A. Nakashima and T. Sueda, “Adjuvant Gemcitabine Plus S-1 Chemotherapy Improves Survival after Aggressive Surgical Resection for Advanced Biliary Carcinoma,” Annals of Surgery, Vol. 250, No. 6, 2009, pp. 950-956.
doi:10.1097/SLA.0b013e3181b0fc8b
|
[15]
|
H. Oettle, S. Post, P. Neuhaus, K. Gellert, J. Langrehr, K. Ridwelski, H. Schramm, J. Fahlke, C. Zuelke, C. Burkart, K. Gutberlet, E. Kettner, H. Schmalenberg, K. Weigang-Koehler, W. O. Bechstein, M. Niedergethmann, I. SchmidtWolf, L. Roll, B. Doerken and H. Riess, “Adjuvant Chemotherapy with Gemcitabine vs. Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial,” Journal of the American Medical Association, Vol. 297, No. 3, 2007, pp. 267-277. doi:10.1001/jama.297.3.267
|
[16]
|
H. Ueno, T. Kosuge, Y. Matsuyama, J. Yamamoto, A. Nakao, S. Egawa, R. Doi, M. Monden, T. Hatori, M. Tanaka, M. Shimada and K. Kanemitsu, “A Randomised Phase III Trial Comparing Gemcitabine with Surgery-Only in Patients with Resected Pancreatic Cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer,” British Journal of Cancer, Vol. 101, No. 6, 2009, pp. 908-915. doi:10.1038/sj.bjc.6605256
|
[17]
|
L. H. Sobin and C. Wittekind, “International Union against Cancer, TNM Classification of Malignant Tumors,” 6th Edition, Wiley-Liss, New York, 2002.
|
[18]
|
M. M. Oken, R. H. Creech, D. C. Tormey, J. Horton, T. E. Davis, E. T. McFadden and P. P. Carbone, “Toxicity and Response Criteria of the Eastern Cooperative Oncology Group,” American Journal of Clinical Oncology, Vol. 5, No. 6, 1982, pp. 649-655.
doi:10.1097/00000421-198212000-00014
|
[19]
|
“Japanese Society of Biliary Surgery: Classification of Biliary Tract Carcinoma,” 5th Edition, Kanehara, 2003.
|